相关费用：选择性费用 ︾Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
USD 4000/ EUR 3840/ GBP 3200（Patent Highlights、Correction、Journal Watch、Letter in Reply、Industry News、Priority Paper Evaluation、Research Highlights、Technology Report、Analytical Focus、Abstract、Case History、Special Feature、Device Evaluation、Troubleshooting Forum、Introduction、Book Review、Corrigendum、Systematic Review）
USD 5500/ EUR 5330/ GBP 4400（Plain Language Summary）
If you choose not to publish Open Access in this journal, there is no Article Publishing Charge (APC).
For invited content there are no submission fees or page charges.
Colour figures will be reproduced in colour in your online article free of charge.
All Podcasts in this journal are published on an open access basis so they are freely accessible to all wanting to understand the latest research. Therefore, there is an article publishing charge (APC) to cover the costs associated with publishing the podcast article. The APC to publish a Podcast in this journal is $2,500 / £2,000 / €2,423 / AUD 3,490, plus VAT or other local taxes where applicable in your country. There is no submission charge.
出版地址：FUTURE MEDICINE LTD , UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB
期刊简介：Regenerative medicine《再生医学》（月刊）. Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology.
